Recce Pharmaceuticals Ltd announces positive efficacy of RECCE® 327

Recce Pharmaceuticals Ltd (ASX: $RCE) has announced positive efficacy of RECCE® 327 (R327) against Neisseria gonorrhoeae (N. gonorrhoeae) in a study conducted by Murdoch Children's Research Institute. The study demonstrated significant bactericidal activity with an approximate 4-log (99.99%) reduction in bacterial shedding after three days of treatment, and a 3.5-log (>99.9%) reduction after five days of treatment.

Executive Commentary on Efficacy Against Neisseria gonorrhoeae

James Graham, Chief Executive Officer of Recce Pharmaceuticals Ltd, emphasized the significance of the study's findings, stating, 'The need for a new class of anti-infectives could not be greater, especially against a lethal pathogen such as N. gonorrhoeae. The data from this study, along with the previous findings, emphasise the capability of R327 to demonstrate broad spectrum activity against antibiotic-resistant bacteria, even with repeated use.'

Summary of Positive Efficacy Against Neisseria gonorrhoeae

Recce Pharmaceuticals Ltd (ASX: $RCE) has demonstrated positive efficacy of RECCE® 327 (R327) against Neisseria gonorrhoeae (N. gonorrhoeae) in a study conducted by Murdoch Children's Research Institute. The results showed significant bactericidal activity, with an approximate 4-log (99.99%) reduction in bacterial shedding after three days of treatment, and a 3.5-log (>99.9%) reduction after five days of treatment. The company's Chief Executive Officer, James Graham, highlighted the importance of developing new anti-infectives, especially against lethal pathogens like N. gonorrhoeae, and expressed confidence in R327's broad spectrum activity against antibiotic-resistant bacteria.